Fly News Breaks for February 21, 2018
SBPH
Feb 21, 2018 | 10:36 EDT
B. Riley FBR analyst Madhu Kumar reiterates a Buy rating on Spring Bank Pharmaceuticals with a $30 price target following the company's Q4 results. The analyst says the company remains an undervalued mid-stage hepatitis B therapy play.
News For SBPH From the Last 2 Days
There are no results for your query SBPH